Quantbot Technologies LP Trims Stake in Privia Health Group, Inc. (NASDAQ:PRVA)

Quantbot Technologies LP lessened its position in Privia Health Group, Inc. (NASDAQ:PRVA) by 40.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 22,331 shares of the company’s stock after selling 15,044 shares during the quarter. Quantbot Technologies LP’s holdings in Privia Health Group were worth $437,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Nordea Investment Management AB raised its holdings in Privia Health Group by 33.1% in the fourth quarter. Nordea Investment Management AB now owns 349,773 shares of the company’s stock worth $6,953,000 after purchasing an additional 86,910 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Privia Health Group by 1.3% in the 4th quarter. Rhumbline Advisers now owns 287,200 shares of the company’s stock worth $5,615,000 after acquiring an additional 3,658 shares in the last quarter. Franklin Resources Inc. lifted its position in Privia Health Group by 2.2% during the 3rd quarter. Franklin Resources Inc. now owns 1,300,240 shares of the company’s stock valued at $23,092,000 after acquiring an additional 28,480 shares during the period. Barclays PLC boosted its stake in Privia Health Group by 240.3% during the third quarter. Barclays PLC now owns 224,018 shares of the company’s stock worth $4,079,000 after acquiring an additional 158,188 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Privia Health Group by 8.4% in the third quarter. JPMorgan Chase & Co. now owns 188,384 shares of the company’s stock worth $3,430,000 after purchasing an additional 14,641 shares during the period. 94.48% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on PRVA shares. JMP Securities set a $29.00 target price on shares of Privia Health Group in a report on Friday, February 28th. JPMorgan Chase & Co. boosted their target price on Privia Health Group from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Friday, November 29th. Piper Sandler raised their price target on Privia Health Group from $25.00 to $40.00 and gave the company an “overweight” rating in a report on Friday, February 28th. Stephens reaffirmed an “overweight” rating and issued a $26.00 price target on shares of Privia Health Group in a research report on Thursday, January 2nd. Finally, Needham & Company LLC reissued a “buy” rating and set a $30.00 price objective on shares of Privia Health Group in a research report on Friday, March 21st. One equities research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $26.67.

Privia Health Group Stock Down 1.4 %

Shares of Privia Health Group stock opened at $22.59 on Friday. Privia Health Group, Inc. has a twelve month low of $15.92 and a twelve month high of $26.04. The company’s 50 day moving average is $23.80 and its 200 day moving average is $21.16. The company has a market cap of $2.72 billion, a price-to-earnings ratio of 225.92, a price-to-earnings-growth ratio of 3.47 and a beta of 0.85.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.